Combination of obesity medication tirzepatide and menopause hormone therapy fuels weight loss
Using tirzepatide and menopause hormone therapy at the same time leads to increased weight loss in postmenopausal women with overweight or obesity compared to use of tirzepatide treatment alone
Intermittent energy restriction may improve outcomes in people with obesity and type 2 diabetes
Intermittent energy restriction, time-restricted eating and continuous energy restriction can all improve blood sugar levels and body weight in people with obesity and type 2 diabetes
Intermittent fasting as effective for weight loss as traditional dieting, says study
Alternate - day fasting - a form of intermittent fasting that involves a 24-hour fast on alternate days - was found to offer the greatest short-term benefit, although the researchers caution that longer studies are needed to confirm the results.
Weight-loss drugs may help patients ‘catch up’ if behavioral therapy fails
Adding an anti-obesity medication alongside behavioral therapy produced significantly more weight loss in patients who initially struggled with the therapy, a study in Nature Medicine showed.
Tirzepatide produces clinically meaningful weight loss for at least 3 years in non-diabetic overweight adults: Trial
Once-weekly treatment with tirzepatide can produce clinically meaningful and sustained weight loss for at least three years in adults with overweight or obesity who do not have diabetes